Products
Tarperprumig Biosimilar Bispecific Single-Domain Antibody (Albumin × Properdin) for Research
Cat No.: GMP-Bios-INN-1408
Anti-ALB therapeutic antibody (Pre-made Tarperprumig biosimilar,Bispecific Single Domains (VH-VH')) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tarperprumig (development code ALXN-1820) is a humanized bispecific single-domain antibody targeting complement factor properdin (CFP) and albumin. It is developed by Alexion Pharmaceuticals for Sickle cell disease in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1408-1mg | 1mg | |
| GMP-Bios-INN-1408-10mg | 10mg | |
| GMP-Bios-INN-1408-100mg | 100mg | |
| GMP-Bios-INN-1408-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tarperprumig biosimilar, Bispecific Single Domains (VH-VH'), Anti-ALB;CFP Antibody: Anti-Albumin/ALB/HSA/FDAHT therapeutic antibody |
| INN Name | Tarperprumig |
| Target | ALB;CFP |
| Format | Bispecific Single Domains (VH-VH') |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;na |
| VD LC | na;na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None;8q6r:A:B |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Alexion Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Sickle cell disease |
| Production | na |
| Development Tech | na |
